A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
Clinical trial NCT06694805 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06694805
- Sponsor
- ViiV Healthcare
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-12-02
- Primary completion
- 2026-08-19
- Enrollment
- 326
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.